We are 100% patient-focused.
Our team works tirelessly every day with one urgent goal in mind: Accelerating breakthroughs patients can feel in their everyday lives. We strive to make progress in the following key areas by evaluating risk, opportunities, and challenges through a patient-focused lens:
Speed treatments that can slow, stop or reverse the progression of Parkinson's disease
Speed better treatments for the currently unaddressed or under-addressed symptoms of Parkinson's disease
Speed treatments to address or avoid the debilitating side effects of current Parkinson's disease drugs
We are obsessed with efficiency.
We operate with a focused sense of optimistic urgency to find a cure for Parkinson's and to ensure the development of improved therapies for people living with Parkinson's today. We won't stop until a cure is found. We're on it.
We won't stop until a cure is found.
We take pride in all our accomplishments so far. But ultimately we have only one definition of success: Scientific solutions that produce tangible improvements in patients' lives.
We are risk-takers and problem-solvers.
From inception, MJFF has invested in high-risk, high-reward research targets; an approach that in 10 short years has transformed the broader approach in the PD research field.
Our model is different.
It is accepted practice among private disease research funders that the most important decisions -- how to allocate donor-raised dollars -- are made by external scientific advisors and boards. We bucked this model from day one in favor of building an in-house team of formally trained PhDs and business-trained project managers.
The information provided in this website was supported by Grant/Cooperative Agreement Number U59DD000906 from the Centers for Disease Control and Prevention (CDC). The contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC.
Copyright © of The Board of Trustees of the University of Alabama